Effect of neoadjuvant chemotherapy on breast cancer phenotype, ER/PR and HER2 expression - Implications for the practising oncologist
- PMID: 27062316
- DOI: 10.1016/j.ejca.2016.03.006
Effect of neoadjuvant chemotherapy on breast cancer phenotype, ER/PR and HER2 expression - Implications for the practising oncologist
Abstract
Purpose: To assess the effect of neoadjuvant chemotherapy (NACT) on breast cancer characteristics, hormone receptors and human epidermal growth factor receptor 2 (HER2) expression and whether testing should be repeated on residual tumours.
Material and methods: Patients with primary operable breast cancer who received NACT at a single United Kingdom tertiary referral centre were included. Tumour type, grade (including details of mitotic grade, tubule formation and pleomorphism), oestrogen receptor (ER), progesterone receptor (PR) and HER2 status were compared between pre-treatment and post-treatment residual samples using tissue microarrays. A control group of paired core and excision tumours from patients who did not receive NACT was also assessed.
Results: Two hundred forty-six cases and 113 controls were included. Pathological complete response (path CR) was achieved in 21.5% of patients. In those patients failing to achieve a path CR, a change in the histological type was noted in 29 out of 178 cases (16.3%, p<0.001) with increase in the lobular and metaplastic types. Downgrading occurred in 28.8%, due to significant reduction in mitotic rate and prominent tubule formation. A change in ER/PR/HER2 status occurred in 12%, 14.5% and 7.1% of cases, respectively, predominantly as a switch from negative to positive status for ER and from positive to negative status for HER2. Further alterations in expression levels were also noted. Minimal changes in the low ER/PR expressors and the HER2 2+ tumours were found in the control group.
Conclusion: Significant changes in tumour morphology, grade, hormone receptors and HER2 status occur following NACT. We recommend testing on residual invasive carcinoma. A switch from negative to positive status warrants offering endocrine/trastuzumab-based therapy to this group of patients.
Keywords: Breast cancer; HER2; Neoadjuvant chemotherapy; Oestrogen receptor; Progesterone receptor.
Copyright © 2016 Elsevier Ltd. All rights reserved.
Similar articles
-
Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.Asian Pac J Cancer Prev. 2012;13(8):4119-23. Asian Pac J Cancer Prev. 2012. PMID: 23098527
-
Estrogen receptor (ER), progesterone receptor (PR), and HER2 expression pre- and post- neoadjuvant chemotherapy in primary breast carcinoma: a single institutional experience.Int J Clin Exp Pathol. 2012;5(6):530-6. Epub 2012 Jul 29. Int J Clin Exp Pathol. 2012. PMID: 22949935 Free PMC article.
-
[Comparison of histopathologic changes and expression of biomarkers in breast carcinoma before and after neoadjuvant chemotherapy].Zhonghua Bing Li Xue Za Zhi. 2011 Jul;40(7):465-70. Zhonghua Bing Li Xue Za Zhi. 2011. PMID: 22088373 Chinese.
-
Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer.Cancer Treat Rev. 2011 Oct;37(6):422-30. doi: 10.1016/j.ctrv.2010.11.006. Epub 2010 Dec 21. Cancer Treat Rev. 2011. PMID: 21177040 Review.
-
Receptor Status after Neoadjuvant Therapy of Breast Cancer: Significance and Implications.Pathobiology. 2022;89(5):297-308. doi: 10.1159/000521880. Epub 2022 May 30. Pathobiology. 2022. PMID: 35636403 Review.
Cited by
-
Impact of neoadjuvant compared to adjuvant chemotherapy on prognosis in patients with hormone-receptor positive / HER2-negative breast cancer: A propensity score matching population-based study.Breast. 2024 Aug;76:103741. doi: 10.1016/j.breast.2024.103741. Epub 2024 May 9. Breast. 2024. PMID: 38759576 Free PMC article.
-
The combination of breast cancer PDO and mini-PDX platform for drug screening and individualized treatment.J Cell Mol Med. 2024 May;28(9):e18374. doi: 10.1111/jcmm.18374. J Cell Mol Med. 2024. PMID: 38722288 Free PMC article.
-
Changes in HER2 status and survival outcomes in patients with non-pathological complete response after neoadjuvant targeted treatment.Medicine (Baltimore). 2023 Sep 29;102(39):e34903. doi: 10.1097/MD.0000000000034903. Medicine (Baltimore). 2023. PMID: 37773875 Free PMC article.
-
Change in Main Histological Type of Invasive Breast Cancer From Ductal to Lobular Carcinoma by Neoadjuvant Chemotherapy.Cureus. 2023 Aug 20;15(8):e43816. doi: 10.7759/cureus.43816. eCollection 2023 Aug. Cureus. 2023. PMID: 37731440 Free PMC article.
-
Locally Advanced Breast Cancer: Response Evaluation to Neoadjuvant Chemotherapy by Clinico-Histopathological Parameters and Molecular Imaging.Indian J Surg Oncol. 2023 Jun;14(2):279-287. doi: 10.1007/s13193-023-01711-1. Epub 2023 Feb 6. Indian J Surg Oncol. 2023. PMID: 37324312 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous